CA2576233C — Conjugate comprising an antagomir and a ligand
Assigned to Alnylam Pharmaceuticals Inc · Expires 2016-03-15 · 10y expired
What this patent protects
This invention relates to composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression. Specifically, the invention provides a conjugate comprising an oligonucleotide agent and a ligand, wherein at least one subunit havin…
USPTO Abstract
This invention relates to composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression. Specifically, the invention provides a conjugate comprising an oligonucleotide agent and a ligand, wherein at least one subunit having a formula (I) is incorporated into said oligonucleotide agent: (see formula I)
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.